CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
治疗交叉点：将 CD19 CAR-T 细胞的获益从肿瘤拓展至自身免疫
英文原题：Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity.
查看英文原题
Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
抗CD19 CAR-T 细胞是过去十年科学突破之一，曾使B细胞白血病和淋巴瘤患者获得显著缓解。如今，这类工程化细胞疗法正拓展至自身免疫性疾病领域，并已缓解系统性红斑狼疮（SLE）、特发性炎性肌病和系统性硬化症患者的疾病症状。[1]
展开英文摘要原文
Anti-CD19 CAR T cells were among the last decade's scientific breakthroughs, achieving remarkable remissions in patients with B cell leukemias and lymphomas. Now, the engineered cell therapies are traversing disease indications into autoimmunity and resolving disease symptoms in patients with systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis. 1 .
论文信息
- 作者
- Sosnoski HM、Posey AD Jr
- 第一作者单位
- Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.United States
- 通讯作者单位
- Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA. Electronic address: aposey@pennmedicine.upenn.edu.United States
- 文献类型
- 评论
- 期刊
- Cell stem cell2024 Apr 4
- 原文标识
- PubMed 38579681 · DOI 10.1016/j.stem.2024.03.006